1SXP logo

SCHOTT Pharma AG & Co. KGaA Stock Price

XTRA:1SXP Community·€2.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

1SXP Share Price Performance

€17.62
-8.03 (-31.31%)
€19.43
Fair Value
€17.62
-8.03 (-31.31%)
9.3% undervalued intrinsic discount
€19.43
Fair Value
Price €17.62
AnalystConsensusTarget €19.43
AnalystHighTarget €25.90
AnalystLowTarget €13.00

1SXP Community Narratives

·
Fair Value €19.43 9.3% undervalued intrinsic discount

Advanced Drug Delivery And Capacity Investments Will Shape Future Success

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value €25.9 32.0% undervalued intrinsic discount

Aging Population And Biologics Growth Will Fuel Advanced Packaging

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value €13 35.5% overvalued intrinsic discount

Intensifying Climate Mandates And Protectionism Will Erode Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
€13
35.5% overvalued intrinsic discount
Revenue
5.49% p.a.
Profit Margin
14.77%
Future PE
13.24x
Price in 2029
€15.49
€25.9
32.0% undervalued intrinsic discount
Revenue
7.31% p.a.
Profit Margin
16.96%
Future PE
22.27x
Price in 2029
€30.71

Trending Discussion

Updated Narratives

1SXP logo

1SXP: Higher Discount Rate And Lower P/E Will Pressure Future Returns

Fair Value: €13 35.5% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
1SXP logo

1SXP: Lebanon Capacity Expansion And 2026 Guidance Will Support Future Upside

Fair Value: €19.43 9.3% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
1SXP logo

1SXP: Lower Discount Rate And Solid Margins Will Support Undervalued Shares

Fair Value: €25.9 32.0% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

0 Risks
3 Rewards

SCHOTT Pharma AG & Co. KGaA Key Details

€991.2m

Revenue

€664.8m

Cost of Revenue

€326.5m

Gross Profit

€183.6m

Other Expenses

€142.8m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 12, 2026
0.95
32.94%
14.41%
23.7%
View Full Analysis

About 1SXP

Founded
1884
Employees
4839
CEO
Christian Mias
WebsiteView website
www.schott-pharma.com

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

Recent 1SXP News & Updates

Narrative Update Jul 01

1SXP: Higher Discount Rate And Lower P/E Will Pressure Future Returns

Analysts have reduced their price target for SCHOTT Pharma KGaA from €14.00 to €13.00, reflecting updated assumptions regarding discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for SCHOTT Pharma KGaA SCHOTT Pharma inaugurated new production lines for standard and sterile ready-to-use glass vials in Lebanon, Pennsylvania, aimed at a wide range of injectable drugs including biologics, vaccines, and emergency room medications.
Narrative Update Jun 17

1SXP: Lebanon Capacity Expansion And 2026 Guidance Will Support Future Upside

Analysts have maintained their fair value estimate for SCHOTT Pharma KGaA at €19.43, with only minor adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions leading to a marginally updated price target framework. What’s in the News for SCHOTT Pharma KGaA SCHOTT Pharma inaugurated expanded vial production lines in Lebanon, Pennsylvania, covering both standard and sterile ready to use glass vials for biologics, vaccines, complex injectable therapies and emergency room medications.

Recent updates

No updates